# Scott Clarke

> Scott Clarke is the CEO of CatalYm GmbH, a Munich-based biotech company developing visugromab, a monoclonal antibody targeting GDF-15 to reverse cancer immunotherapy resistance. With over 20 years in biopharmaceuticals - spanning Roche's global oncology partnering, BioMarin, Tizona Therapeutics, and Ambagon Therapeutics - Clarke joined CatalYm in January 2025 to lead the company's $319M-funded push through Phase 2b clinical trials, building on visugromab's striking Phase 1/2a results published in Nature showing durable responses lasting 28-32+ months in multiple solid tumor types.

- **Role:** CEO at CatalYm GmbH
- **Organizations:** CatalYm GmbH, Ambagon Therapeutics, Tizona Therapeutics, Trishula Therapeutics, Roche, BioMarin Pharmaceutical
- **Nationality:** American
- **Education:** B.S. Chemical Engineering, University of California, Berkeley, M.S. Biotechnology, Northwestern University, MBA, London Business School
- **Known for:** Led CatalYm into Phase 2b clinical development for visugromab, with first patient dosed in NSCLC trial (2025), Oversaw $85M Series A for Ambagon Therapeutics (2022), Led Tizona Therapeutics through FDA IND approval for first-in-class anti-CD39 antibody TTX-030

## Career timeline

- **Early career** — BioMarin Pharmaceutical - Senior Vice President of Product Development, contributed to multiple approved medicines
- **Pre-2019** — Roche - Global Head of Oncology Partnering and Head of Asia and Emerging Markets Partnering
- **2019** — Appointed CEO of Tizona Therapeutics, led FDA IND approval for anti-CD39 antibody TTX-030
- **2020** — Founded and served as initial CEO of Trishula Therapeutics (spinoff from Tizona), advanced $105M AbbVie R&D partnership
- **2022** — Ambagon Therapeutics CEO - led $85M Series A financing, advancing molecular glue platform targeting disordered proteins
- **2025-01** — Appointed CEO of CatalYm GmbH, initiated global Phase 2b clinical development program for visugromab

## Achievements

- Led CatalYm into Phase 2b clinical development for visugromab, with first patient dosed in NSCLC trial (2025)
- Oversaw $85M Series A for Ambagon Therapeutics (2022)
- Led Tizona Therapeutics through FDA IND approval for first-in-class anti-CD39 antibody TTX-030
- Structured $105M AbbVie R&D partnership through Trishula Therapeutics spinoff
- CatalYm's Phase 1/2a visugromab data published in Nature (2024) showing 28-32+ month median duration of responses
- CatalYm closed $150M Series D (July 2024) prior to Clarke joining, bringing total funding to ~$319M

## Latest updates

- **2025-01** — Appointed CEO of CatalYm GmbH, company simultaneously initiates global Phase 2b program for visugromab
- **2025-01** — First patient dosed in Phase 2b trial of visugromab in combination with chemoimmunotherapy in metastatic non-squamous NSCLC
- **2024-07** — CatalYm closes $150M Series D led by Canaan Partners and Bioqube Ventures
- **2024** — CatalYm Phase 1/2a visugromab data published in Nature showing durable responses (19-32+ months) across multiple tumor types

## Links

- Website: https://catalym.com/team_mf/scottclarke/
- LinkedIn: http://www.linkedin.com/in/scott-clarke-713a441

---

Profile page: https://yespress.io/scott-clarke
Published by YesPress — https://yespress.io
Last updated: 2026-05-11